Thrombosis Research
Volume 125, Supplement 1 , Pages S60-S62, April 2010

Long-term expression of canine FVIIa in hemophilic dogs

  • Paris Margaritis

      Affiliations

    • Corresponding Author InformationThe Children's Hospital of Philadelphia, Abramson Research Center, Rm. 302, 3615 Civic Center Blvd., Philadelphia, PA 19104, U.S.A. Tel.: +1 267 426 7262; fax: +1 215 590 3660.

The Children's Hospital of Philadelphia, Division of Hematology, Philadelphia, PA 19104, USA

published online 22 February 2010.

Abstract 

The traditional treatment for hemophilia has been by protein replacement. This is complicated by the development of inhibitory antibodies to the infused factor (Factor VIII [FVIII] or Factor IX [FIX]). High-dose infusion of recombinant activated Factor VII (rFVIIa) has a long track record of success in such patients but its short-half life limits its use in prophylaxis. We have developed an alternative strategy by continuous expression of activated FVII from a transgene that is introduced into the host by means of gene transfer. For this, we modified the FVII cDNA to introduce a cleavage site between the light and heavy chain that would generate a FVII molecule secreted in the two-chain, activated form. Using viral-mediated delivery and expression from a liver-specific promoter (or as a transgenic approach) we demonstrated the long-term hemostatic efficacy of this approach in hemophilic mice. Subsequently, we used the canine version of our modified FVII and via gene transfer, showed multi-year phenotypic correction in hemophilic dogs, clearly evident by the absence of spontaneous bleeds that are characteristic in this animal model. No adverse events were observed throughout the study. Remarkably, clinical benefit was also observed in one treated dog despite the lack of hemostatic effect by in vitro assays. Overall, the results in this large animal model of hemophilia indicate the potential of gene-based continuous expression of activated FVII as a therapeutic strategy for hemophilia or other coagulation defects currently treated by rFVIIa.

Abbreviations: FVII, Factor VII, FVIII, Factor VIII, FIX, Factor IX, FX, Factor X, (AAV), Adeno-associated virus, PACE, Paired basic Amino acid Cleaving Enzyme, PT, prothrombin time, aPTT, activated partial thromboplastin time, mFVIIa, murine FVIIa, cFVIIa, canine FVIIa, cFVII, canine FVII, vg, vector genome, WBCT, whole blood clotting time, hAAT, human alpha1 antitrypsin, ApoE, Apoliprotein E, TEG, thromboelastography

Keywords: Factor VIIa, canine, animal model, gene transfer, hemophilia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0049-3848(10)00093-9

doi:10.1016/j.thromres.2010.01.040

Thrombosis Research
Volume 125, Supplement 1 , Pages S60-S62, April 2010